Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 22:2:691689.
doi: 10.3389/fpain.2021.691689. eCollection 2021.

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome

Prapaporn Boonma  1   2   3 , Jordan M Shapiro  4 , Emily B Hollister  1   2 , Shyam Badu  1   2 , Qinglong Wu  1   2 , Erica M Weidler  5   6   7 , Bincy P Abraham  8 , Sridevi Devaraj  1   2 , Ruth Ann Luna  1   2 , James Versalovic  1   2 , Margaret M Heitkemper  9 , Tor C Savidge  1   2 , Robert J Shulman  5   6   7
Affiliations

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome

Prapaporn Boonma et al. Front Pain Res (Lausanne). .

Abstract

Background: Little is known regarding the clinical impact of treatment and treatment duration of probiotic VSL#3 on gut and microbiome function in irritable bowel syndrome (IBS). As part of a safety trial, we assessed the effect of VSL#3 treatment duration on abdominal pain, stooling, gut permeability, microbiome composition and function. Methods: Adults with IBS were randomized into an open label trial to receive the probiotic VSL#3 for 4 or 8 weeks. Adverse events, abdominal pain, and stooling patterns were recorded daily. Gut permeability, fecal bile acid levels, and microbiome composition were profiled at baseline and after treatment. Results: Fifteen subjects completed the trial (4-week: n = 8; 8-week: n = 7). Number of pain episodes decreased in both groups (P = 0.049 and P = 0.034; 4- vs. 8-week, respectively). Probiotic organisms contained in VSL#3 were detected in feces by whole shotgun metagenomic sequencing analysis and relative abundances of Streptococcus thermophilus, Bifidobacterium animalis, Lactobacillus plantarum, and Lactobacillus casei subsp. paraccasei correlated significantly with improved abdominal pain symptoms and colonic permeability at study completion. Although abdominal pain correlated significantly with the detection of probiotic species at study completion, a composite view of gut microbiome structure showed no changes in community diversity or composition after VSL#3 treatment. Conclusions: Probiotic organisms identified in stool correlated significantly with improvement in colonic permeability and clinical symptoms, prompting future studies to investigate the mechanistic role of VSL#3 and colonic permeability in IBS pathophysiology in a larger randomized controlled trial. Clinical Trial Registration: www.clinicaltrials.gov, Identifier: NCT00971711.

Keywords: VSL#3; bile acids; irritable bowel syndrome; microbiome; permeability; probiotic.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Consort diagram of probiotic VSL#3 treatment in patients with irritable bowel syndrome.
Figure 2
Figure 2
Relative abundance of organisms found in VSL#3 in stool after both 4- and 8-weeks of treatment.
Figure 3
Figure 3
Species-level relative abundances of community members after both 4- and 8-weeks of treatment.
Figure 4
Figure 4
Beta-diversity analysis of MetaPhlAn2 species profile. ANOSIM was used to compare baseline vs. follow-up samples.
Figure 5
Figure 5
Colonic permeability (percent sucralose recovery) of probiotic VSL#3 treatment in 4- and 8-weeks group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. (2015) 313:949-58. 10.1001/jama.2015.0954 - DOI - PubMed
    1. van Tilburg MA, Hyman PE, Walker L, Rouster A, Palsson OS, Kim SM, et al. . Prevalence of functional gastrointestinal disorders in infants and toddlers. J Pediatr. (2015) 166:684-9. 10.1016/j.jpeds.2014.11.039 - DOI - PubMed
    1. Lewis ML, Palsson OS, Whitehead WE, van Tilburg MAL. Prevalence of functional gastrointestinal disorders in children and adolescents. J Pediatr. (2016) 177:39-43.e3. 10.1016/j.jpeds.2016.04.008 - DOI - PubMed
    1. Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. . The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. (2017) 66:1075-82. 10.1136/gutjnl-2015-311240 - DOI - PubMed
    1. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. (2013) 368:578-9. 10.1056/NEJMc1214185 - DOI - PubMed

Associated data